Remdesivir—to be marketed in the United States as Veklury—will be indicated for adults and pediatric patients 12 years of age and older who have forms of COVID-19 serious enough to require hospitalization, and who weigh at least 40 kg (88 pounds).
The team sought to determine whether unacylated-ghrelin (AUG) modulated hippocampal plasticity and memory function and whether plasma levels of acyl-ghrelin and UAG were associated with dementia in humans.
Preliminary findings from a trial involving cancer patients taking immune checkpoint treatment with PD-L1 inhibitors reveal that simultaneous treatment with angiotensin receptor II blockers (ARBs) improve patients’ responses.
The conjugate specifically releases the anticancer agent in cancer cells along with a drug-resistance inhibitor to effectively treat cancers without concern over drug resistance.
The study’s authors say that using the assay can lead to earlier detection of PD and, since it can identify patients with early onset of the disease, aid better recruitment for clinical trials.
The discovery that SARS-CoV-2 virus binds to neuropilin-1—in addition to ACE2—may help explain why the virus is so transmissible compared with other coronaviruses and why it affects so many cells around the body.
There are many connections between oral health and overall health besides diabetes, cardiovascular disease, and arthritis. The researchers’ findings may open a door of understanding for other inflammatory diseases and might even relate to COVID-19.
The OneOncology Research Network (OneR), a subsidiary of OneOncology, will provide operational, regulatory, and research support services with the aim of more efficiently executing multi-center clinical trials.
Ten years after starting the project, the Human Proteome Organization has completed a 90.4% read of the human proteome, knowledge essential for diagnosing and treating many human diseases and for advancing a more personalized approach to medicine.
University of Vermont researchers found that a species of gut microbiome bacteria called Lactobacillus reuteri—commonly used in probiotics— can increase disease severity in a mouse model of multiple sclerosis (MS), but only in genetically susceptible animals.